Did Gilead just lower the bar on crucial remdesivir trials for Covid-19? Switching endpoints, amping up trial size stir analysts' fears — and hopes
To say Gilead’s remdesivir is in the R&D spotlight would be one of the great understatements of the year.
The most advanced late-stage antiviral now in development for Covid-19 is seen as a potential treatment for populations deeply frightened of being killed by the new virus, offering a possible calming effect for markets where panic runs deep — if the data are positive. And that has analysts reading any tea leaves that come their way.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,600+ biopharma pros reading Endpoints daily — and it's free.